These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26002555)

  • 1. Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma.
    Bousquet G; El Bouchtaoui M; Leboeuf C; Battistella M; Varna M; Ferreira I; Plassa LF; Hamdan D; Bertheau P; Feugeas JP; Damotte D; Janin A
    Oncotarget; 2015 Aug; 6(22):19279-89. PubMed ID: 26002555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
    Taniguchi H; Ito S; Ueda T; Morioka Y; Kayukawa N; Ueno A; Nakagawa H; Fujihara A; Ushijima S; Kanazawa M; Hongo F; Ukimura O
    Biochem Biophys Res Commun; 2017 Apr; 485(2):267-271. PubMed ID: 28235487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.
    Kouba EJ; Eble JN; Simper N; Grignon DJ; Wang M; Zhang S; Wang L; Martignoni G; Williamson SR; Brunelli M; Luchini C; Calió A; Cheng L
    Mod Pathol; 2016 Nov; 29(11):1347-1357. PubMed ID: 27469331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma.
    Massari F; Ciccarese C; Bria E; Porta C; La Russa F; Knuutila S; Artibani W; Porcaro AB; Bimbatti D; Modena A; Sava T; Tortora G; Cheng L; Eccher A; Cima L; Pedron S; Ghimenton C; Martignoni G; Brunelli M
    Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):39-43. PubMed ID: 26509904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
    Semeniuk-Wojtaś A; Stec R; Szczylik C
    Urol Oncol; 2016 May; 34(5):215-20. PubMed ID: 26850779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations in metastatic renal cell carcinoma detected by comparative genomic hybridization: correlation with clinical and histological data.
    Junker K; Moravek P; Podhola M; Weirich G; Hindermann W; Janitzky V; Schubert J
    Int J Oncol; 2000 Nov; 17(5):903-8. PubMed ID: 11029490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).
    Yang Y; Vocke CD; Ricketts CJ; Wei D; Padilla-Nash HM; Lang M; Sourbier C; Killian JK; Boyle SL; Worrell R; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Linehan WM
    Genes Chromosomes Cancer; 2017 Oct; 56(10):719-729. PubMed ID: 28736828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis.
    Knezović Florijan M; Ozretić P; Bujak M; Pezzè L; Ciribilli Y; Kaštelan Ž; Slade N; Hudolin T
    Urol Oncol; 2019 Sep; 37(9):578.e1-578.e10. PubMed ID: 30948335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens.
    Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Arndt H; Paeslack U; Werner M; Tan HK; Jonas U
    Int J Cancer; 1995 Dec; 64(6):399-406. PubMed ID: 8550242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Cell Carcinomas in Vinylidene Chloride-exposed Male B6C3F1 Mice Are Characterized by Oxidative Stress and TP53 Pathway Dysregulation.
    Hayes SA; Pandiri AR; Ton TV; Hong HH; Clayton NP; Shockley KR; Peddada SD; Gerrish K; Wyde M; Sills RC; Hoenerhoff MJ
    Toxicol Pathol; 2016 Jan; 44(1):71-87. PubMed ID: 26682919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
    Goswami RS; Patel KP; Singh RR; Meric-Bernstam F; Kopetz ES; Subbiah V; Alvarez RH; Davies MA; Jabbar KJ; Roy-Chowdhuri S; Lazar AJ; Medeiros LJ; Broaddus RR; Luthra R; Routbort MJ
    Clin Cancer Res; 2015 Jun; 21(11):2644-51. PubMed ID: 25695693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
    Saeed K; Ojamies P; Pellinen T; Eldfors S; Turkki R; Lundin J; Järvinen P; Nisen H; Taari K; Af Hällström TM; Rannikko A; Mirtti T; Kallioniemi O; Östling P
    Int J Cancer; 2019 Mar; 144(6):1356-1366. PubMed ID: 30125350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.
    de Velasco G; Wankowicz SA; Madison R; Ali SM; Norton C; Duquette A; Ross JS; Bossé D; Lalani AA; Miller VA; Stephens PJ; Young L; Hakimi AA; Signoretti S; Pal SK; Choueiri TK
    Br J Cancer; 2018 May; 118(9):1238-1242. PubMed ID: 29674707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiam1 mutations in human renal-cell carcinomas.
    Engers R; Zwaka TP; Gohr L; Weber A; Gerharz CD; Gabbert HE
    Int J Cancer; 2000 Nov; 88(3):369-76. PubMed ID: 11054665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Bui TO; Dao VT; Nguyen VT; Feugeas JP; Pamoukdjian F; Bousquet G
    Eur Urol; 2022 Apr; 81(4):349-361. PubMed ID: 34991918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of preclinical models of aggressive renal cell carcinomas.
    Varna M; Bousquet G; Ferreira I; Goulard M; El-Bouchtaoui M; Artus PM; Verine J; de Kerviler E; Hernandez L; Leboeuf C; Escudier B; Legrès L; Setterblad N; Soliman H; Feugeas JP; Janin A; Bertheau P
    Int J Clin Exp Pathol; 2014; 7(6):2950-62. PubMed ID: 25031714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma.
    Lang H; Béraud C; Bethry A; Danilin S; Lindner V; Coquard C; Rothhut S; Massfelder T
    Oncotarget; 2016 Sep; 7(37):59336-59359. PubMed ID: 27449081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic heterogeneity of human renal cell carcinoma.
    Naito S; Kumazawa J; von Eschenbach AC; Fidler IJ
    Urol Int; 1991; 47 Suppl 1():90-5. PubMed ID: 1949389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.
    Turajlic S; Xu H; Litchfield K; Rowan A; Chambers T; Lopez JI; Nicol D; O'Brien T; Larkin J; Horswell S; Stares M; Au L; Jamal-Hanjani M; Challacombe B; Chandra A; Hazell S; Eichler-Jonsson C; Soultati A; Chowdhury S; Rudman S; Lynch J; Fernando A; Stamp G; Nye E; Jabbar F; Spain L; Lall S; Guarch R; Falzon M; Proctor I; Pickering L; Gore M; Watkins TBK; Ward S; Stewart A; DiNatale R; Becerra MF; Reznik E; Hsieh JJ; Richmond TA; Mayhew GF; Hill SM; McNally CD; Jones C; Rosenbaum H; Stanislaw S; Burgess DL; Alexander NR; Swanton C; ;
    Cell; 2018 Apr; 173(3):581-594.e12. PubMed ID: 29656895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of molecular genetic markers to demonstrate the effect of organ environment on clonal dominance in a human renal-cell carcinoma grown in nude mice.
    Staroselsky AN; Radinsky R; Fidler IJ; Pathak S; Chernajovsky Y; Frost P
    Int J Cancer; 1992 Apr; 51(1):130-8. PubMed ID: 1563832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.